What Codex Genetics does

Codex Genetics is a precision genomics company founded in 2013 and headquartered in Hong Kong, operating an accredited molecular diagnostics platform that delivers Next-Generation Sequencing-based clinical genetic testing for hereditary cancers, neurodegenerative diseases, cardiovascular disorders, pharmacogenomics, neurodevelopmental conditions, rare and undiagnosed diseases, and cancer screening/monitoring (including liquid biopsy). Its technology stack combines Illumina NextSeq 2000 sequencing with the proprietary CoGenesis® Bioinformatics Platform for DNA alignment and variant annotation, and includes plasma-based single-molecule immuno-detection of Alzheimer's biomarkers (p-tau217, Aβ42/40 ratio, NfL) alongside APOE genotyping. The company maintains dual ISO 15189 (HOKLAS) and ISO 27001 certifications, achieves 99.9% sequencing accuracy validated by GenQA/UK NEQAS, and holds CAP accreditation for APOE genotyping.

The portfolio comprises a CoGenesis® brand family of 41 tests including CoGenesis® Cancer, CoGenesis® Neuro, CoGenesis® BRCA-Pro (29-gene hereditary breast/ovarian panel), CoGenesis® CVD, and an Alzheimer's Disease Plasma Biomarker Panel, supplemented by whole-genome sequencing and the exclusive Hong Kong distribution of C2N Diagnostics' PrecivityAD2™ Alzheimer's blood test. Codex serves three customer segments — patients, healthcare providers, and biopharma/research institutions — through distinct portals. Patients access tests directly via the shop.codexgenetics.com e-commerce storefront; healthcare providers requisition tests through a dedicated For Providers portal with downloadable forms and direct WhatsApp/phone clinical support; biopharma clients engage for research services and clinical trial management.

Revenue is generated predominantly on a unit-pricing, one-time test basis with per-test pricing ranging from $100 to over $2,000 depending on complexity. The company partners with ZA Insure to broaden insured-patient access and serves over 200 healthcare partners across Hong Kong. The business has been primarily bootstrapped since the $41,250 Cyberport Hong Kong seed round in 2014, with no subsequent disclosed institutional funding rounds, parent company, or acquisitions.

Name

Codex Genetics

Legal name

Codex Genetics Limited

Website

https://codexgenetics.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Hong Kong-based molecular diagnostics company providing NGS-based genetic testing for hereditary cancer, neurodegenerative, cardiovascular, and pharmacogenomic conditions. It serves patients, clinicians, and biopharma via clinician referrals and direct e-commerce, powered by its proprietary CoGenesis® bioinformatics platform.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics & Genetic Testing Services

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

Keywords

• Hereditary cancer testing
• Molecular diagnostics services
• Pharmacogenomics testing
• Next-generation sequencing
• Neurodegenerative disease panels

Headquarters

HQ city

Wan Chai

HQ country

Hong Kong SAR China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Others

Revenue model

1. Clinical Genetic Testing Services: Codex Genetics generates revenue through clinical genomic tests ordered by healthcare providers and directly by patients via their E-Shop (shop.codexgenetics.com). Tests include hereditary cancer panels, neurodegenerative disease panels, pharmacogenomics, cardiovascular disorder panels, and cancer screening/monitoring. Costs range from $100 to over $2,000 depending on the test complexity.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Codex Genetics operates a clinical molecular diagnostics laboratory providing genetic testing services across hereditary cancer, neurodegenerative disease, pharmacogenomics, cardiovascular disorders, neurodevelopmental conditions, liquid biopsy, and whole-genome sequencing. Tests are delivered under the CoGenesis® brand via Next-Generation Sequencing (Illumina NextSeq 2000) combined with the proprietary CoGenesis® Bioinformatics Platform, and are ordered either by healthcare providers through a dedicated clinical portal or directly by patients via the Codex E-Shop.

Product overview

Codex Genetics offers a molecular diagnostics platform providing genetic testing services across multiple clinical areas including hereditary cancer, neurodegenerative diseases, cardiovascular disorders, neurodevelopmental disorders, drug response (pharmacogenomics), cancer screening, treatment guidance, and monitoring. The portfolio includes branded test panels under the CoGenesis® brand (CoGenesis® Cancer, CoGenesis® Neuro, CoGenesis® BRCA-Pro, CoGenesis® CVD) plus specialized biomarker panels and whole-genome sequencing. The company operates on an NGS-based technology platform using the Illumina NextSeq 2000 System, with bioinformatics analysis powered by the CoGenesis® Bioinformatics Platform. All tests leverage Next-Generation Sequencing for comprehensive analysis and are supported by HKAS HOKLAS accreditation and ISO certifications. The company also provides distribution services for third-party diagnostic products such as the PrecivityAD2 blood test in partnership with C2N Diagnostics.

Differentiator

Problem solved

Functional benefit

Brands

• CoGenesis Cancer: Hereditary cancer test panels including BRCA-Pro, Gastric, Prostate, and Colo tests using Next-Generation Sequencing
• CoGenesis Neuro
• CoGenesis AD
• CoGenesis CVD
• CoGenesis Bioinformatics Platform
• PrecivityAD2

Products and services

• CoGenesis® Cancer Panel Flagship hereditary cancer test panel using Next-Generation Sequencing to detect risks for hereditary cancers, including BRCA-Pro (29-gene hereditary breast and ovarian cancer), Gastric, Prostate, and Colo panels. Delivered with NCCN-aligned actionable recommendations. Turnaround 4-6 working weeks.
• CoGenesis® Neuro Panel Comprehensive genomic panel for unexplained neurological disorders, including APOE genotyping for Alzheimer's disease risk assessment. Aimed at neurologists and patients with neurodegenerative concerns. Turnaround 2-4 weeks for AD/APOE components.
• CoGenesis® BRCA-Pro 29-gene hereditary breast and ovarian cancer test providing risk assessment with well-stratified risk and actionable NCCN-aligned recommendations. Turnaround under 21 days.
• CoGenesis® CVD Comprehensive hereditary cardiovascular disease panel for identifying genetic predispositions to heart conditions. Turnaround approximately 3-4 working weeks.
• Alzheimer's Disease Plasma Biomarker Panel Validated plasma biomarkers for Alzheimer's disease combining APOE genotyping via sequencing with single-molecule immuno-detection of p-tau217, Aβ42/40 ratio, and NfL. Turnaround 14-21 working days. Aligned with NIA-AA 2024 criteria.
• Whole-Genome Sequencing Comprehensive sequencing service covering the entire genome for rare disease diagnoses, diagnostic odyssey resolution, and detailed genetic analysis. Suitable for pediatric developmental delay investigation.
• Liquid Biopsy Non-invasive blood-based testing for cancer detection, screening, treatment guidance, and monitoring, used in oncology workflows.
• Pharmacogenomics (PGx) Drug response genetic testing that personalizes medication and treatment plans based on genetic profiles, including gene-drug interaction summaries to prevent adverse drug reactions and inform prescribing.
• PrecivityAD2 Blood Test Blood-based test for early detection and diagnosis of Alzheimer's disease, distributed by Codex Genetics in Hong Kong under exclusive partnership with C2N Diagnostics; offered to hospitals, specialty clinics, and research centers.

Quantifiable outcome

• Over 90% accuracy compared to cerebrospinal fluid analysis or amyloid PET analysis for the PrecivityAD2 blood test (JAMA-published clinical care study)
• +3 more outcomes

Named customers3 records

Segments7 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered core and minor.

• C2N DiagnosticscoreChannel Partner/ Reseller/ Distributor · 10 March 2026Codex Genetics partnered with C2N Diagnostics to launch the PrecivityAD2™ blood test for Alzheimer's disease diagnosis in Hong Kong. C2N provides its proprietary assay technology and analytical platform; Codex Genetics handles local regulatory compliance, distribution, and patient access to hospitals, specialty clinics, and research centers. The collaboration aims to support early intervention strategies and clinical trial enrollment.
• C2N DiagnosticscoreChannel Partner/ Reseller/ Distributor · 8 August 2025C2N Diagnostics expansion of the PrecivityAD2 blood test to over seven additional countries through six new international partners including Codex Genetics. Codex serves as the exclusive distributor for Hong Kong. The blood test has demonstrated over 90% accuracy compared to cerebrospinal fluid analysis or amyloid PET analysis (JAMA-published study).
• ZA InsureminorChannel Partner/ Reseller/ DistributorCodex Genetics partners with ZA Insure to enhance test accessibility through insurance coverage, allowing patients to potentially offset testing costs through health insurance.

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Prenetics: Hong Kong-headquartered genetic and diagnostic testing company offering hereditary cancer screening, pharmacogenomics, and consumer health tests across Asia. Closest geographic and product peer to Codex Genetics, competing for similar Hong Kong clinical and consumer customers.
• Macrogen: Asia-based (Korea) genomic services and NGS sequencing provider offering clinical and research sequencing, hereditary cancer panels, and bioinformatics. Comparable to Codex in NGS-based clinical panel offerings and target customers across research and clinical markets.
• Color Genomics: US-based genetic testing company specializing in hereditary cancer panels and population health genomics. Directly comparable hereditary cancer testing offering and clinical accuracy emphasis to Codex's CoGenesis® Cancer and BRCA-Pro panels.
• Novogene: China-based genomics services company providing NGS, whole-genome sequencing, and clinical genetic testing across Asia and globally. Directly comparable NGS-based clinical testing menu (hereditary cancer, rare disease, oncology) to Codex's CoGenesis® panels.

Broad incumbents

• Foundation Medicine: US-based molecular diagnostics company (Roche subsidiary) specializing in comprehensive genomic profiling for cancer. Comparable NGS-based cancer genomics testing capability to Codex's CoGenesis® Cancer and liquid biopsy panels.
• Natera: US-based genetic testing company with hereditary cancer (Signatera), reproductive health, and organ transplant testing. Comparable NGS-based clinical genetic testing portfolio and oncology-monitoring positioning similar to Codex's liquid biopsy offering.
• Myriad Genetics: US-based molecular diagnostics leader with strong hereditary cancer franchise (BRACAnalysis, myRisk). Comparable hereditary cancer panel product and NCCN-aligned reporting standard referenced in Codex's BRCA-Pro offering.
• 23andMe: US-based direct-to-consumer genetic testing company offering health risk and carrier screening tests. Comparable consumer-facing hereditary health risk testing business model, though operating at much larger scale and in different geographies.
• BGI Group: Largest Chinese genomics conglomerate offering clinical NGS testing, NIFTY prenatal screening, and cancer diagnostics across Asia. Comparable in menu breadth and Asian market focus, with substantially greater scale and vertically integrated sequencing capacity.

Regional players

• Kingmed Diagnostics: China-based clinical diagnostic laboratory network offering genetic and molecular testing, including hereditary cancer panels, across mainland China. Comparable clinical lab business model with NGS-based testing menu, primarily serving mainland China and not directly competing in Hong Kong.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/codexgenetics

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Codex Genetics